A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis
(2018) In British Journal of Cancer 119(7). p.840-846- Abstract
Background: The role of B-lymphocytes in solid tumours is unclear. Tumour biology studies have implied both anti- and pro-tumoural effects and prognostic studies have mainly linked B-cells to increased survival. This study aimed to analyse the clinical relevance of B-lymphocytes in renal cell cancer (RCC), where information on the prognostic impact is lacking. Methods: Following immunohistochemistry (IHC) stainings with a CD20 antibody, density of CD20+ B-cells was quantified in an RCC discovery- and validation cohort. Associations of B-cell infiltration, determined by CD20 expression or a B-cell gene-signature, and survival was also analysed in 14 publicly available gene expression datasets of cancer, including the kidney clear cell... (More)
Background: The role of B-lymphocytes in solid tumours is unclear. Tumour biology studies have implied both anti- and pro-tumoural effects and prognostic studies have mainly linked B-cells to increased survival. This study aimed to analyse the clinical relevance of B-lymphocytes in renal cell cancer (RCC), where information on the prognostic impact is lacking. Methods: Following immunohistochemistry (IHC) stainings with a CD20 antibody, density of CD20+ B-cells was quantified in an RCC discovery- and validation cohort. Associations of B-cell infiltration, determined by CD20 expression or a B-cell gene-signature, and survival was also analysed in 14 publicly available gene expression datasets of cancer, including the kidney clear cell carcinoma (KIRC) dataset. Results: IHC analyses of the discovery cohort identified a previously unrecognised subgroup of RCC patients with high infiltration of CD20+ B-cells. The B-cell-high subgroup displayed significantly shorter survival according to uni- and multi-variable analyses. The association between poor prognosis and high density of CD20+ B-cells was confirmed in the validation cohort. Analyses of the KIRC gene expression dataset using the B-cell signature confirmed findings from IHC analyses. Analyses of other gene expression datasets, representing 13 different tumour types, indicated that the poor survival-association of B-cells occurred selectively in RCC. Conclusion: This exploratory study identifies a previously unrecognised poor-prognosis subset of RCC with high density of CD20-defined B-cells.
(Less)
- author
- Sjöberg, Elin ; Frödin, Magnus ; Lövrot, John ; Mezheyeuski, Artur ; Johansson, Martin LU ; Harmenberg, Ulrika ; Egevad, Lars ; Sandström, Per and Östman, Arne
- organization
- publishing date
- 2018-10-08
- type
- Contribution to journal
- publication status
- published
- subject
- in
- British Journal of Cancer
- volume
- 119
- issue
- 7
- pages
- 7 pages
- publisher
- Nature Publishing Group
- external identifiers
-
- scopus:85054505901
- pmid:30293996
- ISSN
- 0007-0920
- DOI
- 10.1038/s41416-018-0266-8
- language
- English
- LU publication?
- yes
- id
- 0368a061-9648-4ff2-b480-f6a1fc81dc37
- date added to LUP
- 2018-11-13 10:30:17
- date last changed
- 2024-06-10 22:13:43
@article{0368a061-9648-4ff2-b480-f6a1fc81dc37,
abstract = {{<p>Background: The role of B-lymphocytes in solid tumours is unclear. Tumour biology studies have implied both anti- and pro-tumoural effects and prognostic studies have mainly linked B-cells to increased survival. This study aimed to analyse the clinical relevance of B-lymphocytes in renal cell cancer (RCC), where information on the prognostic impact is lacking. Methods: Following immunohistochemistry (IHC) stainings with a CD20 antibody, density of CD20+ B-cells was quantified in an RCC discovery- and validation cohort. Associations of B-cell infiltration, determined by CD20 expression or a B-cell gene-signature, and survival was also analysed in 14 publicly available gene expression datasets of cancer, including the kidney clear cell carcinoma (KIRC) dataset. Results: IHC analyses of the discovery cohort identified a previously unrecognised subgroup of RCC patients with high infiltration of CD20+ B-cells. The B-cell-high subgroup displayed significantly shorter survival according to uni- and multi-variable analyses. The association between poor prognosis and high density of CD20+ B-cells was confirmed in the validation cohort. Analyses of the KIRC gene expression dataset using the B-cell signature confirmed findings from IHC analyses. Analyses of other gene expression datasets, representing 13 different tumour types, indicated that the poor survival-association of B-cells occurred selectively in RCC. Conclusion: This exploratory study identifies a previously unrecognised poor-prognosis subset of RCC with high density of CD20-defined B-cells.</p>}},
author = {{Sjöberg, Elin and Frödin, Magnus and Lövrot, John and Mezheyeuski, Artur and Johansson, Martin and Harmenberg, Ulrika and Egevad, Lars and Sandström, Per and Östman, Arne}},
issn = {{0007-0920}},
language = {{eng}},
month = {{10}},
number = {{7}},
pages = {{840--846}},
publisher = {{Nature Publishing Group}},
series = {{British Journal of Cancer}},
title = {{A minority-group of renal cell cancer patients with high infiltration of CD20+B-cells is associated with poor prognosis}},
url = {{http://dx.doi.org/10.1038/s41416-018-0266-8}},
doi = {{10.1038/s41416-018-0266-8}},
volume = {{119}},
year = {{2018}},
}